Annex F Questionnaire (one per chemical)

Chemical name (as used by the	Chlordecone
POPs Review Committee	Cilioraccone
(POPRC))	

Explanatory note:

note:
1. This chemical is undergoing a risk management evaluation. It has already satisfied the screening criteria set out in paragraph 4 (a) of Article 8 of the Convention. A risk profile has also been completed for this chemical in accordance with paragraph 6 of Article 8 and with Annex E to the Convention.

Introductory informa	Hazardous Substances Control Group
Name of the submitting Party/observer	Bureau of Cosmetics and nazar Food and Drug Administration Ministry of Public Health
Contact details (name, telephone, e-mail) of the submitting	Somchai Prechathaveekid Director of the Hazardous Substances Control Group psomchai@health.moph.go.th Tel. 66 2 590 7300
Party/observer Date of submission	February 16, 2005

Additional Annex E information	0 	 		
(i) Production data, including quantity and location		 	<u>.</u> .	
(ii) Uses		 		
(iii) Releases, such as discharges, losses and emissions			<u> </u>	

Explanatory note:

ote:

This information was requested for preparation of the risk profile in accordance with Annex E of the Convention. The POPRC would like to collect more information on these items. If you have additional or updated information, kindly provide it.

•			
A. Efficacy and efficiency (provide summary inform	of possible control me ation and relevant ref	asures in meeting risl erences):	c reduction goals
(i) Describe possible control measures			
(ii) Technical feasibility		÷	

(iii) Costs, including environmental and health costs

Explanatory notes:

- 3. If relevant, provide information on uses for which there may be no suitable alternative or for which the analysis of socio-economic factors justify the inclusion of an exemption when considering listing decisions under the Convention. Detail the negative impacts on society that could result if no exemption were permitted.
- 4. "Risk reduction goals" could refer to targets or goals to reduce or eliminate releases from intentional production and use, unintentional production, stockpiles, wastes, and to reduce or avoid risks associated with long-range environment transport.
- 5. Provide the costs and benefits of implementing the control measure, including environmental and health costs and benefits.
- 6. Where relevant and possible "costs" should be expressed in US dollars per year.

B. Alternatives (produreferences):	ets and p	rocesse	s) (prov	ide su	mmary	inform	ation a	ind rele	vant
(i) Describe alternatives								<u>.</u>	
(ii) Technical feasibility							 .		
(iii) Costs, including environmental and health costs							٠.		
(iv) Efficacy									
(v) Risk							·.		
(vi) Availability		-		-					
(vii) Accessibility									

Explanatory notes:

- 7. Provide a brief description of the alternative product or process and, if appropriate, the sector(s), use(s) or user(s) for which it would be relevant.
- If several alternatives could be envisaged for the chemical under consideration, including non-chemical alternatives, provide information under this section for each alternative.
- 9. Specify for each proposed alternative whether it has actually been implemented (and give details), whether it has only reached the trial stage (again, with details) or whether it is just a proposal.
- 10. The evaluation of the efficacy should include any information on the performance, benefits, costs, and limitations of potential alternatives.
- Specify if the information provided is connected to the specific needs and circumstances of developing countries.
- 12. The evaluation of the risk of the alternative should include any information on whether the proposed alternative has been thoroughly tested or evaluated in order to avoid inadvertently increasing risks to human health and the environment. The evaluation should include any information on potential risks associated with untested alternatives and any increased risk

- over the life-cycle of the alternative, including manufacture, distribution, use, maintenance and disposal.
- 13. If the alternative has not been tried or tested, information on projected impacts may also be
- 14. Information or comments on improving the availability and accessibility of alternatives may also be useful.

C. Positive and/or negative (provide summary inform	ve impacts on society of implementing possible control measures nation and relevant references):
(i) Health, including public, environmental and occupational health	
(ii) Agriculture, including aquaculture and forestry	
(iii) Biota (biodiversity)	
(iv) Economic aspects	
(v) Movement towards sustainable development	
(vi) Social costs	

Explanatory notes:

- 15. Socio-economic considerations could include:
 - Any information on the impact (if any), costs and benefits to the local, national and regional
 economy, including the manufacturing sector and industrial and other users (e.g., capital costs
 and benefits associated with the transition to the alternatives); and impacts on agriculture and
 forestry;
 - Any information on the impact (if any) on the wider society, associated with the transition to
 alternatives, including the negative and positive impacts on public, environmental, and
 occupational health. Consideration should also be given to the positive and negative impacts on
 the natural environment and biodiversity.
 - Information should be provided on how control measures fit within national sustainable development strategies and plans.

D. Waste and dispos clean-up of contamin	D. Waste and disposal implications (in particular, obsolete stocks of pesticides and clean-up of contaminated sites) (provide summary information and relevant references):							
(i) Technical feasibility								
(ii) Costs								

Exp	lan	ato	rv	note:

Specify if the information provided is connected to the specific needs and circumstances of developing countries.

E. Access to information and public education (provide summary information and relevant references):							
				-			
		4					
,							

Explanatory note:

17. Please provide details here of access to information and public education with respect to both control measures and alternatives.

F. Status of control and monitoring capac	eity (provide su	mmary informa	ation and re	levant
references):	· ·			_

Explanatory note:

18. With regard to control capacity, the information required is on legislative and institutional frameworks for the chemical under consideration and their enforcement. With regard to monitoring capacity, the information required is on the technical and institutional infrastructure for the environmental monitoring and biomonitoring of the chemical under consideration, not monitoring capacity for alternatives.

G. Any national or regional control actions already taken, including information on alternatives, and other relevant risk management information:

According to the Hazardous Substances Control Act B.E. 2535 (1992) which is the country's major act to manage chemicals, production, import, export or possession of chlordecone for use in household and public health program are prohibited. There is no any record of chlordecone or chlordecone-containing products registered to the FDA.

Explanatory notes:

- 19. Actions or measures taken could include prohibitions, phase-outs, restrictions, cleanup of contaminated sites, waste disposal, economic incentives, and other non-legally binding initiatives.
- 20. Information could include details on whether these control actions have been cost-effective in providing the desired benefits and have had a measurable impact on reducing levels in the environment and contributed to risk reduction.

H.	H. Other relevant information for the risk management evaluation:						
	· · · · · ·						
				•	•		

Explanatory notes:

21. The above list of items is only indicative. Any other relevant information for the risk management evaluation should also be provided.

I. Other information requested by the POP	RC:			
[Note to the Secretariat]	V			
		•	<u> </u>	